Skip to main content

ALPROLIX® prophylaxis improved pain and physical activity levels vs baseline1

 

Proportion of patients never/rarely/seldom reporting outcomes at the end of B-LONG vs baseline (post hoc)*1​

Illustration of a joint with radiating lines, representing a painful swelling.

Painful swellings

20% increase from baseline (44% to 64% [n=73]) 
OR: 2.32 (95% CI: 1.33–4.03 [p=0.004])

Illustration of a person kicking a football.

Avoidance of sport (e.g., football)

22% increase from baseline (8% to 30% [n=50])
OR: 4.93 (95% CI: 1.77–13.74 [p=0.002])

Illustration of a knee joint with lightning symbols, representing painful joints.

Painful joints

16% increase from baseline (28% to 44% n=78)
OR: 1.97 (95% CI: 1.29–3.00 [p=0.003])

Illustration of a person walking.

Difficulty walking as far as they wanted to

20% increase from baseline (43% to 63% [n=76])
OR: 2.23 (95% CI: 1.41–3.53 [p=0.001])

Following ALPROLIX prophylaxis in B-LONG, a significantly greater proportion of patients reported never/rarely/seldom having swellings, painful joints, avoiding sport or having difficulty walking as far as they wanted vs baseline1

B-LONG STUDY DESIGN

← JOINT protection
REAL-WORLD EXPERIENCE →

*The primary objective of this post-hoc analysis was to describe the change from baseline to end of study in PROs related to pain and physical activity. The analysis included patients who received weekly dose-adjusted (n=63) or interval-adjusted (n=29) ALPROLIX prophylaxis and completed the Haemophilia-Specific Quality of Life questionnaire for adolescents (Haem-A-QoL; 12–17 years) or adults (Haem-A-QoL; ≥18 years) at baseline and end of study. A separate analysis evaluating overall change in physical activity during B-LONG included patients from the pooled prophylaxis arms, in addition to the episodic treatment (n=27). Item responses were merged into two categories: ‘never/rarely/seldom’ vs ‘sometimes/often/all the time’. In addition, for assessment of the pain items, merged categories were further defined as ‘no pain’ and ‘pain’, respectively. 1

CI, confidence interval; OR, odds ratio; PRO, patient-related outcomes; QoL, quality of life.

References

1. Astermark J, et al. Haemophilia.  2021;28(1):18–26.  2. ALPROLIX UK Summary of Product Characteristics. 3. ALPROLIX EU Summary of Product Characteristics. 



ALPROLIX is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). ALPROLIX can be used for all age groups.2,3

Adverse events should be reported. Reporting forms and information can be found, for United Kingdom: via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. For Ireland: via HPRA Pharmacovigilance website www.hpra.ie. Adverse events should also be reported to Swedish Orphan Biovitrum Ltd by email at [email protected] or by calling +44 (0) 800 111 4754.

 

PP-30709